Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.
Tamoxifen was granted FDA approval on 30 December 1977.
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients
- Conditions
- Premenopausal Breast CancerHormone Receptor-positive Breast Cancer
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT04997941
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- Conditions
- ER+ Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 1100
- Registration Number
- NCT04985266
- Locations
- 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 75
- Registration Number
- NCT04961632
- Locations
- 🇸🇬
National Cancer Centre, Singapore, Singapore
Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial
- Conditions
- Vaginal Bleeding
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Virginia Commonwealth University
- Registration Number
- NCT04933240
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸Shanthi Ramesh, Richmond, Virginia, United States
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: MK-6194-matching placebo
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT04924114
- Locations
- 🇺🇸
IHS. Health, LLC ( Site 0104), Kissimmee, Florida, United States
🇺🇸Pinnacle Clinical Research ( Site 0103), San Antonio, Texas, United States
🇩🇪Charite Research Organisation GmbH ( Site 0201), Berlin, Germany
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Tolmar Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04906395
- Locations
- 🇺🇸
Texas Oncology- Deke Slayton Cancer Center, Webster, Texas, United States
🇧🇷Hospital Araujo Jorge, Goiania, Goias, Brazil
🇺🇸Marin Cancer Care, Inc, Greenbrae, California, United States
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- Conditions
- Breast Cancer Stage IV
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 60
- Registration Number
- NCT04765098
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
- Conditions
- Ductal Carcinoma in SituExtensive DiseaseMastectomy
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Institut Cancerologie de l'Ouest
- Target Recruit Count
- 262
- Registration Number
- NCT04666961
- Locations
- 🇫🇷
Institut Curie - Site de Paris, Paris, France
🇫🇷Institut de Cancérologie de l'Ouest, Saint Herblain, France
🇫🇷ICO - Site Paul Papin, Angers, France
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 1354
- Registration Number
- NCT04666805
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.